APOB and diabetes mellitus: Activation of sphingomyelinase by generating ceramide and creating a cascade of bioactive lipids are known to contribute to CVD risk [24], which strongly suggests that one of the important residual risk factors for the development of CVD and other complications of diabetes, not addressed by statin therapy, is likely to be the increased levels of sphingolipids carried by Apo B-containing lipoproteins.